

Healthcare Headline Transactions

Accelerating Contract Research Organization (CRO)

Consolidation

Four major CRO transactions in July

(at right)

Three major CRO

transactions in May

and June:

- inVentiv Health

- Albany Molecular

- PAREXEL



aptuit evotec

Target



Acquiror

Covance Inc. entered into a definitive agreement to acquire Chiltern International Limited from Galaxy Limited Partnership and others for \$1.2 billion

Acquisition Synopsis

- Chiltern International Limited is a CRO which provides clinical development, scientific services, and collaborative technologies for pharmaceutical and biotech companies worldwide
- Covance Inc. is a CRO which provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries worldwide
- Evotec AG (XTRA:EVT) entered into a definitive agreement to acquire Aptuit LLC from Welsh, Carson, Anderson & Stowe for \$300.0 million
- Aptuit LLC is a CRO which provides drug discovery and development services
- Evotec AG is a CRO which provides drug discovery solutions to pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide
- Implied Enterprise Value Multiples: 3.2x Revenue, 25.8x EBITDA



- Amatsigroup, a contract development and manufacturing organization (CDMO), provides services throughout preclinical and clinical phases
- Eurofins Scientific SE is a CRO which provides various analytical testing services worldwide







- ICON Public Limited Company (NasdaqGS:ICLR) signed an exclusive agreement to acquire MAPI Developpement for \$142.0 million
 - MAPI Developpement, SAS is a CRO which provides research services for academia, life science researchers, biologics, medical device companies, and the pharmaceutical industry
 - ICON Public Limited Company is a CRO which provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries














Enterprise Value / LTM EBITDA



LTM Gross & EBITDA Margins



LTM Stock Price Index



Selected Bi	otechnology /	Pharmaceutical Transactions	Selected Healthcare Services Transactions		
Target	Acquiror	Target Description	Target	Acquiror	Target Description
Protein Sciences Corporation	Sanofi Pasteur Inc.	Protein Sciences Corporation develops, manufactures, and commercializes vaccines and biopharmaceuticals Transaction Value: \$650.0 million, up to an additional \$100.0 million in milestones	Eliving Pharmaceutical Co., Ltd.	Fujian Building Research Technology Co., Ltd.	Eliving Pharmaceutical Co., Ltd., a contract research organization (CRO), engages in research and development of pharmaceutical products Transaction Value: \$24.4 million
ACAM2000	Emergent BioSolutions Inc. (NYSE:EBS)	ACAM2000 manufactures and distributes a vaccine to cure smallpox Transaction Value: \$97.5 million, up to an additional \$27.5 million in milestones	U-Protein Express BV	ImmunoPrecise Antibodies Ltd. (TSXV:IPA)	U-Protein Express BV, a contract research organization (CRO), produces and markets pre- clinical recombinant proteins and antibodies Transaction Value: \$8.2 million
GlaxoSmithKline plc, Raxibacumab	Emergent BioSolutions Inc	Raxibacumab comprises a fully human monoclonal antibody and is located in the United States	A Place for Mom, Inc.	General Atlantic LLC; Silver Lake	A Place for Mom, Inc. provides assisted living referral services

Selected Life Sciences / Diagnostics Transactions

\$20.0 million in milestones

Transaction Value: \$76.0 million, up to an additional

diagnostic laboratory services in the United States

Transaction Value: \$33.0 million

(NYSE:EBS)

(NYSE:NVTA)

Target Target Description Acquiror Alere Inc., Triage **Quidel Corporation** Alere Inc., Triage MeterPro Assets and B-type MeterPro Assets & B-(NasdaqGS:QDEL) Naturietic Peptide Assay Business comprises type Naturietic diagnostic tests for infectious diseases Transaction Value: \$440.0 million Peptide Assay Unit Celsis International Ltd. designs and manufactures Celsis International Charles River Ltd. Laboratories rapid bacterial detection systems/microbial screening International, Inc. systems for quality control testing needs (NYSE:CRL) Transaction Value: \$210.0 million CombiMatrix Invitae Corporation CombiMatrix Corporation provides clinical molecular

Selected Medical Device Transactions

	Target	Acquiror	Target Description
	Cirtec Medical Systems, LLC	3i Group plc (LSE:III)	Cirtec Medical Systems, LLC provides outsourced engineering, design, and contract manufacturing services for the medical device industry Transaction Value: \$105.3 million
	WPI Holdings Inc.	Convatec Group Plc	WPI Holdings Inc. operates as a distributor of incontinence and related healthcare products in the United States Trnsaction Value: \$120.0 million
	Spirox, Inc.	Entellus Medical, Inc. (NasdaqGM:ENTL)	Spirox, Inc. develops medical devices to treat nasal valve collapse Trnsaction Value: \$81.3 million

Recent TM Capital Healthcare Transactions



Corporation

(NasdaqCM:CBMX)







James I. McLaren

Managing Director

jmclaren@tmcapital.com

212.809.1414





Michael S. Goldman

Managing Director

mgoldman@tmcapital.com

212.809.1419



Paul R. Smolevitz

Managing Director
psmolevitz@tmcapital.com
212.809.1416

TM Capital Corp. is a partner-owned investment banking firm based in New York, Boston and Atlanta, which has completed over 300 transactions with a combined value in excess of \$20 billion. Since 1989, we have advised clients navigating a full range of critical transactions, including complex mergers, acquisitions, debt and equity financings, minority and majority recapitalizations, restructurings, and advisory services including takeover defense, fairness and solvency opinions and valuations. We have built deep industry expertise in key sectors and our team regularly publishes research highlighting current and emerging trends in targeted industries and markets. TM Capital is a member firm of Oaklins, the world's most experienced mid-market M&A advisor with over 700 M&A professionals in over 60 offices operating in the major financial centers in the world. Members have closed over 1,500 transactions totaling more than \$75 billion in value over the past five years.

New York 641 Lexington Ave 30th Floor New York, NY 1<u>0022</u> **Boston** 201 Washington St 32nd Floor Boston, MA 02108 Atlanta 1230 Peachtree Rd NE Suite 550 Atlanta, GA 30309

